All eyenovia Articles
-
471Latest Myopia NewsEyenovia Regains Rights to MicroPine Atropine Spray in U.S. and Canada
January 18, 2024 NEW YORK — Eyenovia has regained the rights to MicroPine, an investigational eight microliter ophthalmic spray of atropine delivered by...
-
1.1KLatest Myopia NewsTreehouse Eyes Sponsors T.H.E. Summit During Vision Expo West
LAS VEGAS – “This category is about to explode, and you are so lucky to be at the forefront of myopia management,”...
-
5.4KClinicalInvestigational and Early-stage Myopia Interventions – A Farsighted View
November 1, 2020 By Thomas Aller, OD, FBCLA Collaborator, BHVI With the increasing incidence of myopia all around the world, predictions of...
-
2.6KLatest Myopia NewsSecond Exclusive License Strengthens Bausch + Lomb’s Global Research Focus on Myopia
Oct. 15, 2020 SYDNEY and LAVAL, QC – Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and Bausch + Lomb, its leading global eye...
-
3.2KLatest Myopia NewsBausch Health Licenses Eyenovia’s Investigational Treatment for the Reduction of Pediatric Myopia Progression
October 12, 2020 Bausch Health Companies and Eyenovia, Inc. (NASDAQ: EYEN) today announced that an affiliate of Bausch Health has acquired an...
-
3.1KLatest Myopia NewsEyenovia, Arctic Vision to Develop and Commercialize MicroPine and MicroLine in Asia
August 11, 2020 NEW YORK and SHANGHAI, China — Eyenovia, Inc., a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose...
-
2.3KLatest Myopia NewsEyenovia Launches Website to Help Parents Find Its CHAPERONE Study
August 11, 2020 Eyenovia, which in June enrolled its first patient in its Phase 3 CHAPERONE study of progressive myopia, this month...
-
13.2KClinicalTopical Low-Dose Atropine: A Global Perspective
June 24, 2020 By Dwight Akerman, OD, MBA, FAAO, FBCLA Chief Medical Editor, Review of Myopia Management The use of atropine to...
-
5.1KLatest Myopia NewsEyenovia Developing a Microdose Treatment for Delivering Atropine
June 12, 2020 The clinical-stage ophthalmic biopharmaceutical company Eyenovia is developing a microdose treatment that is designed to improve the delivery of...